NASDAQ Framework: Vericel Corporation

Advanced therapies for sports medicine and burn care 1.

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company specializing in advanced therapies for the sports medicine and severe burn care markets. The company markets three primary products in the United States: MACI, an autologous cultured chondrocytes on porcine collagen membrane for knee cartilage repair; Epicel, a permanent skin replacement for severe burn patients; and NexoBrid, an ointment for eschar removal in burn care. Vericel combines innovations in biology with medical technologies to offer a highly differentiated portfolio of cell therapies and specialty biologics that repair injuries and restore lives 2 3 4 5.

2: Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. We currently market two autologous cell therapy products and one specialty biologic product in the United States. Personal integrity, teamwork, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us. PRIVACY AND COMMUNITY GUIDELINES When you engage with Vericel social media channels and our content providers on social media, you also agree to abide by the following Community Guidelines (found here: https://bit.ly/3pg3UKQ), which apply in addition to the Terms and Conditions or other legal notices specific to each social media channel. Please note that third-party social media channels also have access to information you share via social media. For more details, read LinkedIn's Privacy Policy here: https://bit.ly/3GF2r5Y. For additional information about privacy at Vericel, please see our Privacy Policy (bit.ly/43ErZcx) and Terms and Conditions of Use (bit.ly/4568Cdx). If you engage with us, you consent and give Vericel permission to communicate with you and to use any information, text and media associated with the interaction or post. View Source3: Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. View Source4: Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone... View Source5: Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. View Source

UNKNOWN

The provided facts do not specify whether Vericel Corporation is still led by its founders or if the founders are heavily involved in the company [f39749-f39757]UNKNOWN

The provided facts do not specify whether Vericel Corporation is still led by its founders or if the founders are heavily involved in the company [f39749-f39757].

LOW RISK

Vericel Corporation has demonstrated robust financial health, with no debt and a solid balance sheet supported by $125 million in cash 6. The company has reported consistent revenue growth, with a 25% increase in total revenue for the recent quarter, surpassing projected guidance 7. Additionally, Vericel has raised its full-year revenue forecast to $238 million to $242 million, indicating strong financial performance and future growth potential 8.

6: "Vericel Corporation (NASDAQ:VCEL) manufactures and sells two advanced cell therapy products: MACI is a cartilage repair product for the treatment of cartilage defects in the knee and Epicel is a permanent skin replacement in the severe burn care field. The company also licenses NexoBrid, which is used to remove eschar in patients with partial or full thickness burns. MACI, which is still <10% penetrated into a $2B addressable market, is the primary growth driver and continues to gain adoption from surgeons and patients due to strong clinical results. Epicel operates in a slower growth segment of the burn market but VCEL maintains high market share. NexoBrid, a product recently approved by the FDA, can be an incremental growth catalyst for VCEL’s burn franchise. VCEL generates solid revenue growth, healthy profit margins, and is supported by a balance sheet with $125m cash and no debt." View Source7: Vericel Corporation (NASDAQ:VCEL) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held Vericel Corporation (NASDAQ:VCEL) at the end of the first quarter which was 16 in the previous quarter. Vericel Corporation (NASDAQ: VCEL) reported a 25% increase in total revenue for the quarter, surpassing the projected guidance range. In addition, the company has raised its full-year revenue forecast to $238 million to $242 million, citing a strong start to the year. While we acknowledge the potential of Vericel Corporation (NASDAQ:VCEL) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. View Source8: Vericel Corporation (NASDAQ:VCEL) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held Vericel Corporation (NASDAQ:VCEL) at the end of the first quarter which was 16 in the previous quarter. Vericel Corporation (NASDAQ: VCEL) reported a 25% increase in total revenue for the quarter, surpassing the projected guidance range. In addition, the company has raised its full-year revenue forecast to $238 million to $242 million, citing a strong start to the year. While we acknowledge the potential of Vericel Corporation (NASDAQ:VCEL) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. View Source

YES

Vericel Corporation has recently launched a new product, NexoBrid, which is an ointment used for eschar removal in burn care 9.

9: “Vericel Corporation (NASDAQ:VCEL) develops advanced cell-therapy products for the sports-medicine and severe-burn-care markets. The company currently sells two primary products, and just launched a third. Both primary products use a cell-therapy technology wherein a portion of skin or a biopsy is taken from a patient, sent to Vericel to be processed, and then returned to the patient to be used in aiding treatment. The sports-medicine product, MACI, is used to replace damaged cartilage in the knee, and results in shorter patient recovery times and better long-term results than other procedures. The MACI product accounts for roughly 80% of total company revenue. The burn-care product, Epicel, is a skin graft, which is used for healing patients with severe burns over a significant portion of their bodies. The newly released third product, Nexobrid, is also for burn care and is an ointment used to remove dead burned skin to improve healing. View Source

Vericel Corporation's product roadmap and expansion strategy from 2024 to 2026 focus on leveraging the strong clinical results and market adoption of its primary products, MACI and Epicel, while also capitalizing on the recent FDA approval of NexoBrid to drive incremental growth in the burn care segment. MACI, which addresses a $2 billion market, remains the primary growth driver, with ongoing efforts to increase its penetration among surgeons and patients. Epicel continues to hold a significant market share in the burn care field, albeit in a slower growth segment. The company aims to sustain its robust revenue growth and healthy profit margins, supported by a solid balance sheet with $125 million in cash and no debt, positioning itself for continued success and expansion in the advanced therapies market 10 11 12.

10: "Vericel Corporation (NASDAQ:VCEL) manufactures and sells two advanced cell therapy products: MACI is a cartilage repair product for the treatment of cartilage defects in the knee and Epicel is a permanent skin replacement in the severe burn care field. The company also licenses NexoBrid, which is used to remove eschar in patients with partial or full thickness burns. MACI, which is still <10% penetrated into a $2B addressable market, is the primary growth driver and continues to gain adoption from surgeons and patients due to strong clinical results. Epicel operates in a slower growth segment of the burn market but VCEL maintains high market share. NexoBrid, a product recently approved by the FDA, can be an incremental growth catalyst for VCEL’s burn franchise. VCEL generates solid revenue growth, healthy profit margins, and is supported by a balance sheet with $125m cash and no debt." View Source11: During the first quarter, Vericel reported earnings results that were above expectations, with revenue up 23% year over year and improved profitability. MACI was the main growth driver with 22% revenue growth, and had the highest number of implants, biopsies and surgeons using it in any quarter since the product launched. The company is approaching 50% penetration of the 5,000 potential surgeons they are targeting. Also, Epicel generated 22% revenue growth and Nexobrid became available in the fourth quarter. The continued growth of Vericel’s core products and the expectations for future revenue from new products drove the positive stock price movement during the quarter.” View Source12: Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. View Source

Sources

1: Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. We currently market two autologous cell therapy products and one specialty biologic product in the United States. Personal integrity, teamwork, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us. PRIVACY AND COMMUNITY GUIDELINES When you engage with Vericel social media channels and our content providers on social media, you also agree to abide by the following Community Guidelines (found here: https://bit.ly/3pg3UKQ), which apply in addition to the Terms and Conditions or other legal notices specific to each social media channel. Please note that third-party social media channels also have access to information you share via social media. For more details, read LinkedIn's Privacy Policy here: https://bit.ly/3GF2r5Y. For additional information about privacy at Vericel, please see our Privacy Policy (bit.ly/43ErZcx) and Terms and Conditions of Use (bit.ly/4568Cdx). If you engage with us, you consent and give Vericel permission to communicate with you and to use any information, text and media associated with the interaction or post. View Source2: Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. We currently market two autologous cell therapy products and one specialty biologic product in the United States. Personal integrity, teamwork, collaboration, and innovative technology are the foundations of our work. We seek to practice transparency in our clinical trials and research, and in our relationships with each other, our patients, and the investors who support us. PRIVACY AND COMMUNITY GUIDELINES When you engage with Vericel social media channels and our content providers on social media, you also agree to abide by the following Community Guidelines (found here: https://bit.ly/3pg3UKQ), which apply in addition to the Terms and Conditions or other legal notices specific to each social media channel. Please note that third-party social media channels also have access to information you share via social media. For more details, read LinkedIn's Privacy Policy here: https://bit.ly/3GF2r5Y. For additional information about privacy at Vericel, please see our Privacy Policy (bit.ly/43ErZcx) and Terms and Conditions of Use (bit.ly/4568Cdx). If you engage with us, you consent and give Vericel permission to communicate with you and to use any information, text and media associated with the interaction or post. View Source3: Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. View Source4: Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone... View Source5: Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. View Source6: "Vericel Corporation (NASDAQ:VCEL) manufactures and sells two advanced cell therapy products: MACI is a cartilage repair product for the treatment of cartilage defects in the knee and Epicel is a permanent skin replacement in the severe burn care field. The company also licenses NexoBrid, which is used to remove eschar in patients with partial or full thickness burns. MACI, which is still <10% penetrated into a $2B addressable market, is the primary growth driver and continues to gain adoption from surgeons and patients due to strong clinical results. Epicel operates in a slower growth segment of the burn market but VCEL maintains high market share. NexoBrid, a product recently approved by the FDA, can be an incremental growth catalyst for VCEL’s burn franchise. VCEL generates solid revenue growth, healthy profit margins, and is supported by a balance sheet with $125m cash and no debt." View Source7: Vericel Corporation (NASDAQ:VCEL) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held Vericel Corporation (NASDAQ:VCEL) at the end of the first quarter which was 16 in the previous quarter. Vericel Corporation (NASDAQ: VCEL) reported a 25% increase in total revenue for the quarter, surpassing the projected guidance range. In addition, the company has raised its full-year revenue forecast to $238 million to $242 million, citing a strong start to the year. While we acknowledge the potential of Vericel Corporation (NASDAQ:VCEL) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. View Source8: Vericel Corporation (NASDAQ:VCEL) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 17 hedge fund portfolios held Vericel Corporation (NASDAQ:VCEL) at the end of the first quarter which was 16 in the previous quarter. Vericel Corporation (NASDAQ: VCEL) reported a 25% increase in total revenue for the quarter, surpassing the projected guidance range. In addition, the company has raised its full-year revenue forecast to $238 million to $242 million, citing a strong start to the year. While we acknowledge the potential of Vericel Corporation (NASDAQ:VCEL) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. View Source9: “Vericel Corporation (NASDAQ:VCEL) develops advanced cell-therapy products for the sports-medicine and severe-burn-care markets. The company currently sells two primary products, and just launched a third. Both primary products use a cell-therapy technology wherein a portion of skin or a biopsy is taken from a patient, sent to Vericel to be processed, and then returned to the patient to be used in aiding treatment. The sports-medicine product, MACI, is used to replace damaged cartilage in the knee, and results in shorter patient recovery times and better long-term results than other procedures. The MACI product accounts for roughly 80% of total company revenue. The burn-care product, Epicel, is a skin graft, which is used for healing patients with severe burns over a significant portion of their bodies. The newly released third product, Nexobrid, is also for burn care and is an ointment used to remove dead burned skin to improve healing. View Source10: "Vericel Corporation (NASDAQ:VCEL) manufactures and sells two advanced cell therapy products: MACI is a cartilage repair product for the treatment of cartilage defects in the knee and Epicel is a permanent skin replacement in the severe burn care field. The company also licenses NexoBrid, which is used to remove eschar in patients with partial or full thickness burns. MACI, which is still <10% penetrated into a $2B addressable market, is the primary growth driver and continues to gain adoption from surgeons and patients due to strong clinical results. Epicel operates in a slower growth segment of the burn market but VCEL maintains high market share. NexoBrid, a product recently approved by the FDA, can be an incremental growth catalyst for VCEL’s burn franchise. VCEL generates solid revenue growth, healthy profit margins, and is supported by a balance sheet with $125m cash and no debt." View Source11: During the first quarter, Vericel reported earnings results that were above expectations, with revenue up 23% year over year and improved profitability. MACI was the main growth driver with 22% revenue growth, and had the highest number of implants, biopsies and surgeons using it in any quarter since the product launched. The company is approaching 50% penetration of the 5,000 potential surgeons they are targeting. Also, Epicel generated 22% revenue growth and Nexobrid became available in the fourth quarter. The continued growth of Vericel’s core products and the expectations for future revenue from new products drove the positive stock price movement during the quarter.” View Source12: Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. View Source